Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alpha-Beta, MycoTox Inc. deal

ABTI will acquire MycoTox, a developer of antifungal drugs and targets,

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE